Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial

Serruys PW., 2012, From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?, Eur Heart J., 33, 16b, 10.1093/eurheartj/ehr384

Serruys PW., 2015, A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial., Lancet., 385, 43, 10.1016/S0140-6736(14)61455-0

Ellis SG., 2015, Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease., N Engl J Med., 373, 1905, 10.1056/NEJMoa1509038

Gao R., 2015, Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial., J Am Coll Cardiol., 66, 2298, 10.1016/j.jacc.2015.09.054

Kimura T., 2015, A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan., Eur Heart J., 36, 3332, 10.1093/eurheartj/ehv435

Stone GW., 2016, 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis., Lancet., 387, 1277, 10.1016/S0140-6736(15)01039-9

Chevalier B., 2016 Aug 27., Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial., EuroIntervention., Epub AOP

Karanasos A., 2015, Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience., Circ Cardiovasc Interv., 8, 5, 10.1161/CIRCINTERVENTIONS.114.002369

Raber L., 2015, Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings., J Am Coll Cardiol., 66, 1901, 10.1016/j.jacc.2015.08.853

Räber L., 2016, Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study., EuroIntervention., 12, 482, 10.4244/EIJY15M08_03

Nakatani S., 2015 Oct 9., Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-L-lactic (PLLA) scaffolds (Absorb) on optical coherence tomo_graphy at baseline and follow-up., EuroIntervention., Epub AOP

Windecker S., 2015, Comparison of a novel biodegradable polymer sirolimus-eluting stent with a dur_able polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial., Circ Cardiovasc Interv., 8, e001441, 10.1161/CIRCINTERVENTIONS.114.001441

Serruys PW., 2010, Comparison of zotarolimus-eluting and everolimus-eluting coronary stents., N Engl J Med., 363, 136, 10.1056/NEJMoa1004130

Puricel S., 2016, Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors., J Am Coll Cardiol., 67, 921, 10.1016/j.jacc.2015.12.019

de la Torre Hernandez JM., 2010, Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)., JACC Cardiovasc Interv., 3, 911, 10.1016/j.jcin.2010.06.010

Räber L., 2012, Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study., Circulation., 125, 1110, 10.1161/CIRCULATIONAHA.111.058560

Onuma Y., 2014, Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)., JACC Cardiovasc Interv., 7, 1400, 10.1016/j.jcin.2014.06.016

Mangiameli A., 2015, Neoatherosclerosis as the cause of late failure of a bioresorbable vascular scaffold., JACC Cardiovasc Interv., 8, 633, 10.1016/j.jcin.2014.11.014

Serruys PW., 2014, Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months., EuroIntervention., 9, 1271, 10.4244/EIJV9I11A217

Maier W., 2002, Exercise-induced coronary artery vasodilation is not impaired by stent placement., Circulation., 105, 2373, 10.1161/01.CIR.0000016360.97819.44

Iannaccone M., 2016 Apr 20., Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis., Eur Heart J Cardiovasc Imaging., Epub AOP

Onuma Y., 2015, Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-Cypher registries., EuroIntervention., 11, 533, 10.4244/EIJY14M06_09

Gutiérrez-Chico JL., 2012, Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography., Circ Cardiovasc Interv., 5, 20-9, s1, 10.1161/CIRCINTERVENTIONS.111.965301

Serruys PW., 2011, Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes., J Am Coll Cardiol., 58, 1578, 10.1016/j.jacc.2011.05.050

de Jaegere P., 1998, Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study)., Eur Heart J., 19, 1214, 10.1053/euhj.1998.1012

Brugaletta S., 2012, Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments., Circ J., 76, 1616, 10.1253/circj.CJ-11-1416

Gomez-Lara J., 2011, Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography., JACC Cardiovasc Interv., 4, 1271, 10.1016/j.jcin.2011.08.016

Sabate M., 2016, Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the ran_domized ABSORB ST-segment elevation myocardial infarction-TROFI II trial., Eur Heart J., 37, 229, 10.1093/eurheartj/ehv500

Sotomi Y., 2016, Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography., Int J Cardiovasc Imaging., 32, 871, 10.1007/s10554-016-0856-6